Avanos Medical (NYSE:AVNS) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Avanos Medical (NYSE:AVNS) posted its quarterly earnings data on Tuesday. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05, FiscalAI reports. The company had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. Avanos Medical updated its FY 2026 guidance to 0.900-1.100 EPS.

Avanos Medical Stock Down 1.6%

AVNS stock opened at $15.22 on Tuesday. The company has a current ratio of 2.38, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average of $12.86 and a two-hundred day moving average of $12.02. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $16.63. The company has a market cap of $706.33 million, a price-to-earnings ratio of -1.49 and a beta of 1.09.

Analysts Set New Price Targets

Several research analysts recently weighed in on AVNS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Wall Street Zen upgraded Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Avanos Medical presently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On Avanos Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Avanos Medical during the 3rd quarter worth approximately $211,000. State of Wyoming lifted its holdings in Avanos Medical by 64.4% in the second quarter. State of Wyoming now owns 17,273 shares of the company’s stock valued at $211,000 after acquiring an additional 6,765 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Avanos Medical by 51.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,594 shares of the company’s stock worth $203,000 after acquiring an additional 5,963 shares during the period. EP Wealth Advisors LLC purchased a new position in Avanos Medical in the fourth quarter worth approximately $201,000. Finally, Brooklyn Investment Group increased its stake in Avanos Medical by 2,033.0% during the third quarter. Brooklyn Investment Group now owns 15,635 shares of the company’s stock worth $181,000 after acquiring an additional 14,902 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.